Gennevilliers, January 6th 2010 - Minvasys announced that the company has received CE Mark approval for its Amazonia Pax® Polymer Free Drug Eluting stent. The Amazonia Pax® is the third generation of coronary DES; abluminal polymer free elution applied on an ultra-thin chromium cobalt platform.This CE approval was authorized by the LNE /G-MED (French Notified Body) and AFSSAPS (French Health Competent Authority) according to the new European Union directive 2007/47/EC.
The latest ultra-thin chromium cobalt stent Amazonia Croco®, recognised for its excellent deliverability, has been designed by Minvasys to optimize arterial wall coverage, offering an outstanding support as drug carrier. Polymer free abluminal Paclitaxel coating developed for Amazonia Pax® combines the proven safety and efficacy of the Paclitaxel to a non-polymeric microdropped spray process releasing the loaded drug within 45 days...
[...]
...About Minvasys
Minvasys created in May 2003, is an international privately held company based in the Paris area, France. Minvasys focuses on bifurcation treatment with dedicated devices. Nile Croco/Pax® for coronary bifurcations and Twin-One® for carotid bifurcations. Next products generations are in progress with the Pax program (Paclitaxel Polymer Free Coating) and an integrated embolic protection system with a self-expendable stent for carotid applications... Minvasys' Press Release -
